Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias

NCT01139970 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01139970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01139970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
June 4, 2010
Completion date
December 1, 2018
Enrollment
66 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p21.3;q23.3); mllt3-kmt2a, adult acute promyelocytic leukemia with t(15;17)(q24.1;q21.2); pml-rara, adult b acute lymphoblastic leukemia, adult b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, adult t acute lymphoblastic leukemia, alkylating agent-related acute myeloid leukemia, chronic myelomonocytic leukemia, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia